Flexion Therapeutics (FLXN) Reports Q4 Loss of $1.97

Flexion Therapeutics (NASDAQ: FLXN) reported Q4 EPS of ($1.97), versus ($23.02) reported last year.

Anticipated Events in 2015

• Announce the results of pivotal Phase 2b trial in the fourth quarter
• Complete final, pivotal Phase 3 clinical trial enrollment for FX006

For earnings history and earnings-related data on Flexion Therapeutics (FLXN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c